Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy
Advances in Diagnosis and Treatment

Iona Novak, PhD; Cathy Morgan, PhD; Lars Adde, PhD; James Blackman, PhD; Roslyn N. Boyd, PhD; Janice Brunstrom-Hernandez, MD; Giovanni Cioni, MD; Diane Damiano, PhD; Johanna Darrah, PhD; Ann-Christin Eliasson, PhD; Linda S. de Vries, PhD; Christa Einspieler, PhD; Michael Fahey, PhD; Darcy Fehlings, PhD; Donna M. Ferriero, MD; Linda Fetters, PhD; Simona Fiori, PhD; Hans Forssberg, PhD; Andrew M. Gordon, PhD; Susan Greaves, PhD; Andrea Guzzetta, PhD; Mijna Hadders-Algra, PhD; Regina Harbourne, PhD; Angelina Kakooza-Mwesige, PhD; Petra Karlsson, PhD; Lena Krumlinde-Sundholm, PhD; Beatrice Latal, MD; Alison Loughran-Fowlds, PhD; Nathalie Maitre, PhD; Sarah McIntyre, PhD; Garey Noritz, MD; Lindsay Pennington, PhD; Domenico M. Romeo, PhD; Roberta Shepherd, PhD; Alicia J. Spittle, PhD; Marelle Thornton, DipEd; Jane Valentine, MRCP; Karen Walker, PhD; Robert White, MBA; Nadia Badawi, PhD

IMPORTANCE Cerebral palsy describes the most common physical disability in childhood and occurs in 1 in 500 live births. Historically, the diagnosis has been made between age 12 and 24 months but now can be made before 6 months’ corrected age.

OBJECTIVES To systematically review best available evidence for early, accurate diagnosis of cerebral palsy and to summarize best available evidence about cerebral palsy–specific early intervention that should follow early diagnosis to optimize neuroplasticity and function.

EVIDENCE REVIEW This study systematically searched the literature about early diagnosis of cerebral palsy in MEDLINE (1956-2016), EMBASE (1980-2016), CINAHL (1983-2016), and the Cochrane Library (1988-2016) and by hand searching. Search terms included cerebral palsy, diagnosis, detection, prediction, identification, predictive validity, accuracy, sensitivity, and specificity. The study included systematic reviews with or without meta-analyses, criteria of diagnostic accuracy, and evidence-based clinical guidelines. Findings are reported according to the PRISMA statement, and recommendations are reported according to the Appraisal of Guidelines, Research and Evaluation (AGREE) II instrument.

FINDINGS Six systematic reviews and 2 evidence-based clinical guidelines met inclusion criteria. All included articles had high methodological Quality Assessment of Diagnostic Accuracy Studies (QUADAS) ratings. In infants, clinical signs and symptoms of cerebral palsy emerge and evolve before age 2 years; therefore, a combination of standardized tools should be used to predict risk in conjunction with clinical history. Before 5 months’ corrected age, the most predictive tools for detecting risk are term-age magnetic resonance imaging (86%-89% sensitivity), the Prechtl Qualitative Assessment of General Movements (98% sensitivity), and the Hammersmith Infant Neurological Examination (90% sensitivity). After 5 months’ corrected age, the most predictive tools for detecting risk are magnetic resonance imaging (86%-89% sensitivity) (where safe and feasible), the Hammersmith Infant Neurological Examination (90% sensitivity), and the Developmental Assessment of Young Children (83% C index). Topography and severity of cerebral palsy are more difficult to ascertain in infancy, and magnetic resonance imaging and the Hammersmith Infant Neurological Examination may be helpful in assisting clinical decisions. In high-income countries, 2 in 3 individuals with cerebral palsy will walk, 3 in 4 will talk, and 1 in 2 will have normal intelligence.

CONCLUSIONS AND RELEVANCE Early diagnosis begins with a medical history and involves using neuroimaging, standardized neurological, and standardized motor assessments that indicate congruent abnormal findings indicative of cerebral palsy. Clinicians should understand the importance of prompt referral to diagnostic-specific early intervention to optimize infant motor and cognitive plasticity, prevent secondary complications, and enhance caregiver well-being.

Published online July 17, 2017.
According to a 2007 report, “Cerebral palsy is a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.”

Cerebral palsy is a clinical diagnosis based on a combination of clinical and neurological signs. Diagnosis typically occurs between age 12 and 24 months. The following 4 motor types exist but may emerge and change during the first 2 years of life: (1) spasticity (85%-91%), (2) dyskinesia (4%-7%), including dystonia and athetosis; (3) ataxia (4%-6%); and (4) hypotonia (2%), which is not classified in all countries. Dyskinesia, ataxia, and hypotonia usually affect all 4 limbs, whereas spasticity is categorized topographically as (1) unilateral (hemiplegia) (38%) and (2) bilateral, including diplegia (lower limbs affected more than upper limbs) (37%) and quadriplegia (all 4 limbs and trunk affected) (24%).

Cerebral palsy is the most common disability in childhood, with a prevalence of 2.1 cases per 1000 in high-income countries. The prevalence is declining in Australia and Europe. Exact rates in countries of low to middle income are less certain but appear to be higher, with worse physical disability, because of greater infectious disease burden and perinatal and perinatal care differences. The complete causal path to cerebral palsy is unclear in approximately 80% of cases, but risk factors are often identifiable from history taking about conception, pregnancy, birth, and the postneonatal period. The full causal path is a complex interplay between several risk factors across multiple epochs, including new evidence suggesting that 14% of cases have a genetic component.

Early diagnosis does not preclude further specific etiological investigation, and identifying a specific etiology does not then preclude individuals from also having cerebral palsy. Genetic advances are likely to soon amend the diagnostic process.

Our primary objective was to systematically review best available evidence for early, accurate diagnosis of cerebral palsy. Our secondary objective was to summarize best available evidence about cerebral palsy-specific early intervention that should follow early diagnosis to optimize neuroplasticity and function.

**Methods**

We conducted a systematic review to develop an international clinical practice guideline in accord with the World Health Organization’s *Handbook for Guideline Development* and the Institute of Medicine’s standards. We followed the Equator Network reporting recommendations outlined in the Appraisal of Guidelines, Research and Evaluation (AGREE) II instrument and the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. We systematically searched MEDLINE (1956-2016), EMBASE (1980-2016), CINAHL (1983-2016), and the Cochrane Library (1988-2016) and hand searched using the following terms: cerebral palsy, diagnosis, detection, prediction, identification, prediction validity, accuracy, sensitivity, and specificity. We included systematic reviews with or without meta-analyses, criteria of diagnostic accuracy, and evidence-based clinical guidelines. Quality was appraised using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) methodological rating checklist for systematic reviews of diagnostic accuracy.

The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework was used to assess quality and formulate recommendations along a 4-part continuum, including strong for, conditional for, conditional against, and strong against. As per the GRADE method, we weighed (1) the balance between desirable and undesirable consequences of different management strategies or not acting; (2) family preferences, including benefits vs risks and inconvenience; and (3) cost. Recommendations were discussed face-to-face among all authors, and the manuscript was reviewed, edited, and agreed on by all coauthors. Authors were clinicians involved in the diagnosis of cerebral palsy, including neurologists, pediatricians, neonatologists, rehabilitation specialists, general practitioners, neuroradiologists, psychiatrists, physical therapists, psychologists, occupational therapists, speech pathologists, nurses, and early educators. Individuals with cerebral palsy and parents also contributed as equal authors, ensuring that recommendations addressed their views and preferences.

**Results**

Six systematic reviews and 2 evidence-based clinical guidelines met inclusion criteria. The methodological quality of the evidence was very high (eTable in the Supplement), enabling strong GRADE recommendations. Many standardized tools exist that predict risk of cerebral palsy early. Best available evidence was summarized (eTable in the Supplement), and a PRISMA diagram summarized study flow (eFigure in the Supplement).

**Advances in Diagnosis: Early Clinical Diagnosis Is Now Possible**

Before age 12 to 24 months was historically regarded as the latent or silent period where cerebral palsy could not be identified accurately. Experts now consider the silent period as outdated because...
cerebral palsy or “high risk of cerebral palsy” can be accurately predicted before age 6 months’ corrected age.

The 3 tools with best predictive validity for detecting cerebral palsy before 5 months’ corrected age are (1) neonatal magnetic resonance imaging (MRI) (86%-89% sensitivity),21,27 (2) the Prechtl Qualitative Assessment of General Movements (GMs) (98% sensitivity),21 and (3) the Hammersmith Infant Neurological Examination (HINE) (90% sensitivity).25 (eTable in the Supplement). After 5 months’ corrected age, the most predictive tools for detecting risk are MRI (86%-89% sensitivity) (where safe and feasible), the HINE (90% sensitivity), and the Developmental Assessment of Young Children (83% C index). High-quality evidence also indicates that a trajectory of abnormal GMs or HINE scores, in combination with abnormal MRI, producing congruent findings, is even more accurate than individual clinical assessments in isolation.21,25

To make an early clinical diagnosis before 6 months’ corrected age, a combination of assessments with strong predictive validity coupled with clinical reasoning is recommended. We have made 12 recommendations from best available evidence (Table 1). A highly experienced clinical team should ideally conduct and interpret the standardized assessments and then communicate the news compassionately.

### Interim High Risk of Cerebral Palsy Clinical Diagnosis

When the clinical diagnosis is suspected but cannot be made with certainty, we recommend using the interim clinical diagnosis of high risk of cerebral palsy until a diagnosis is confirmed. We recommend specifying cerebral palsy because infants with cerebral palsy require and benefit from different early interventions than infants “at risk of developmental delay,” “at risk of autism,” “at risk of harm,” or with “social risk.” When the infant is perceived to be at risk of cerebral palsy, he or she should be referred for cerebral palsy-specific early intervention (see the Advances in Treatment section), with regular medical, neurological, and developmental monitoring from the infant’s pediatrician or neurologist to assist with forming a diagnostic picture. To assign the interim clinical diagnosis of high risk of cerebral palsy, the infant must have motor dysfunction (essential criterion) and at least one of the other 2 additional criteria.

#### Essential Criterion (Required)

**Motor Dysfunction**

In motor dysfunction, the infant’s quality of movement is reduced (eg, absent fidgety GMs)30 or neurologically abnormal (eg, early observable hand asymmetry or suboptimal HINE scores).30 In addition, the infant’s motor activities may be substantially below those expected for chronological age (eg, abnormal score on a standardized motor assessment or parent and caregiver or clinical observations of head lag, not sitting, inability to grasp, or not reaching for a toy when appropriate).

As a caveat, in milder presentations, especially unilateral cerebral palsy, it is possible for an infant to score within the normal range on a standardized motor assessment, while still displaying abnormal movements. For example, an infant with hemiplegia might obtain a normal fine-motor score but complete the assessment one-handed. Similarly, an infant with diplegia may achieve normal upper limb scores and abnormal lower limb scores, producing a combined total motor score within the normal range. Therefore, it is essential that assessments be carried out by a professional skilled at determining atypical movement from variation in typical movement.

#### Additional Criteria (at Least One Required)

**Abnormal Neuroimaging**

Abnormal MRI21,27 with or without serial cranial ultrasound in preterm infants21,28 may identify neuroanatomical abnormalities predictive of cerebral palsy. The most predictive patterns are (1) white matter injury (cystic periventricular leukomalacia or periventricular hemorrhagic infarctions) (56%), (2) cortical and deep gray matter lesions (basal ganglia or thalamus lesions, watershed injury [parasagittal injury], multicystic encephalomalacia, or stroke) (18%), and (3) brain maldevelopments (lissencephaly, pachygyria, cortical dysplasia, polymicrogyria, or schizencephaly) (9%).

**Clinical History Indicating Risk for Cerebral Palsy**

Preconception risks include history of stillbirths, miscarriages, low socioeconomic status, assisted reproduction, and abnormal genetic copy number variations.

Pregnancy risks include genetics, birth defects, multiples, males, maternal thyroid disease or preeclampsia, infection, intrauterine growth restriction, prematurity, and substance abuse.

Perinatal birth risks include acute intrapartum hypoxia-ischemia, seizures, hypoglycemia, jaundice, and infection.

Postneonatal risks include stroke, infection, surgical complications, and accidental and nonaccidental brain injury31 occurring before age 24 months, as per the Surveillance of Cerebral Palsy Europe and Australian Cerebral Palsy Register inclusion criteria.

#### Two Early Detection Pathways Based on Different Risks

Half of all infants with cerebral palsy have high-risk indicators identifiable in the newborn period, enabling early screening31 (eg, prematurity, atypical intrauterine growth, encephalopathy, genetic abnormalities, and seizures). We have described this population as having “newborn-detectable risks for cerebral palsy,” and this pathway occurs before 5 months’ corrected age. For the other half of all infants with cerebral palsy, the pregnancy and labor may have appeared to be uneventful,31 and parents, caregivers, or community-based professionals first notice delayed motor milestones (eg, not sitting at 6 months or hand asymmetry). This finding may be especially true for infants with unilateral cerebral palsy, who often master early rudimentary motor skills, such as smiling, swallowing, and head control, and it is not until they attempt more complex motor skills, such as grasp, that asymmetries become observable. We have described this population as having “infant detectable risks for cerebral palsy,” and this pathway occurs after 5 months’ corrected age. We developed a conceptual framework for early diagnosis based on these 2 pathways to ensure that the most sensitive and specific tools are used to reduce false-positive and false-negative results. The clinical diagnostic pathway algorithm for these 2 groups varies because the tools have different psychometric properties depending on the infant’s age (Figure).

#### Determining Severity

Parents or caregivers will want to learn about the severity of their infant’s physical disability to understand his or her capabilities to plan their future. In infants younger than 2 years, motor severity is difficult to accurately predict for the following reasons: (1) almost half...
<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength of Recommendations and Quality of Evidence</th>
</tr>
</thead>
</table>
| **1.0** The clinical diagnosis of CP can and should be made as early as possible so that:  
- The infant can receive diagnostic-specific early intervention and surveillance to optimize neuroplasticity and prevent complications  
- The parents can receive psychological and financial support (when available) | Strong recommendation based on moderate-quality evidence for infant and parent outcomes |
| **1.1** When the clinical diagnosis is suspected but cannot be made with certainty, the interim clinical diagnosis of high risk of CP should be given so that:  
- The infant can receive diagnostic-specific early intervention and surveillance to optimize neuroplasticity and prevent complications  
- The parents can receive psychological and financial support (when available) | Strong recommendation based on moderate-quality evidence for infant and parent outcomes |
| **2.0** Early standardized assessments and investigations for early detection of CP should always be conducted in populations with newborn-detectable risks (i.e., infants born preterm, infants with neonatal encephalopathy, infants with birth defects, and infants admitted to the NICU) | Strong recommendation based on high-quality evidence of test psychometrics |

#### Early Detection of CP Before 5 mo CA

3.0 Option A: The most accurate method for early detection of CP in infants with newborn-detectable risks and younger than 5 mo (CA) is to use a combination of a standardized motor assessment and neuroimaging and history taking about risk factors

**Standardized motor assessment**

3.1 Test: GMs to identify motor dysfunction (95%-98% predictive of CP), combined with neuroimaging

**Neuroimaging**

3.2 Test: MRI (before sedation is required for neuroimaging) to detect abnormal neuroanatomy in the motor areas of the brain (80%-90% predictive of CP). Note that normal neuroimaging does not automatically preclude the diagnosis of risk of CP

4.0 Option B: In contexts where the GMs assessment is not available or MRI is not safe or affordable (e.g., in countries of low to middle income), early detection of CP in infants with newborn-detectable risks and younger than 5 mo (CA) is still possible and should be carried out to enable access to early intervention

**Standardized neurological assessment**

4.1 Test: HINE (scores <57 at 3 mo are 96% predictive of CP)

**Standardized motor assessment**

4.2 Test: TIMP

#### Early Detection of CP After 5 mo CA

Accurate early detection of CP in those with infant-detectable risks and age 5-24 mo can and should still occur as soon as possible, but different diagnostic tools are required

5.0 Any infant with:  
- (a) Inability to sit independently by age 9 mo, or  
- (b) Hand function asymmetry, or  
- (c) Inability to take weight through the plantar surface (heel and forefoot) of the feet should receive early standardized investigations for CP

6.0 Option A: The most accurate method for early detection of CP in those with infant detectable risks older than 5 mo (corrected for prematurity) but younger than 2 y is to use a combination of a standardized neurological assessment, neuroimaging, and a standardized motor assessment with a history taking about risk factors

**Standardized neurological assessment**

6.1 Test: HINE (90% predictive of CP). Those with HINE scores >73 (at 6, 9, or 12 mo) should be considered at high risk of CP. HINE scores <40 (at 6, 9, or 12 mo) almost always indicate CP, combined with neuroimaging and standardized motor assessments

**Neuroimaging**

6.2 Test: MRI to detect abnormal neuroanatomy in the motor areas of the brain (sedation may be required from >6 wk up to age 2 y). Well-defined lesions can be seen early, but subtle white matter lesions may be difficult to detect owing to rapid growth, myelination, and activity-dependent plasticity. Repeated MRI scans are recommended at age 2 y for infants with initially normal findings on MRI at (12-18 mo) but persistent motor or neurological abnormality, combined with standardized motor assessments

**Standardized motor assessment**

6.3 Test: DAYC for parents to self-report and quantify motor delay (89% predictive of CP). Additional assessments can improve triangulation of findings

6.4 Tests: AIMS (86% predictive of an abnormal motor outcome) and NSMDA (82% predictive of an abnormal motor outcome)

7.0 Option B: In contexts where MRI is not safe or affordable, early detection of CP is still possible in those with infant detectable risks between 5 and 24 mo CA and should be carried out to enable access to early intervention

**Standardized neurological assessment**

7.1 Test: HINE (90% predictive of CP at age 2-24 mo)  
HINE scores at 6, 9, or 12 mo:  
- <73 Indicates high risk of CP  
- <40 Indicates abnormal outcome, usually CP

**Standardized motor assessment**

7.2 Test: DAYC to quantify motor delay (89% predictive of CP)

7.3 Test: MAI to quantify motor delay (73% predictive of CP)

(continued)
of all infants younger than 2 years have their Gross Motor Function Classification System (GMFCS) reclassified, (2) little natural history data exist about infants with cerebral palsy (eg, the onset of spasticity, dyskinesia, or contractures), (3) motor skills are developing, (4) the presence or absence of hypertonia changes and evolves, and (5) there is rapid brain growth and use-dependent reorganization in response to caregiving and therapy. In children 2 years or older, severity is reliably classified using the 5-level GMFCS Extended & Revised.25 In infants younger than 2 years, prediction of motor severity should be made cautiously using standardized tools, including the cutoff scores on the HINE, combined with neuroimaging data.25 Parents or caregivers may mistakenly assume that the diagnosis means their child will need a wheelchair and have an intellectual disability. However, in high-income countries, population data indicate that 2 in 3 individuals with cerebral palsy will walk, 3 in 4 will talk, and 1 in 2 will have normal intelligence.5

### Determining Motor Type and Topography

The motor types and topography of cerebral palsy may emerge and change during the first 2 years of life. Cerebral palsy can be difficult to accurately classify early, but clinical signs exist.33-37 (Table 2). For example, the onset of spasticity may occur after age 1 year; therefore, the absence of early detectable spasticity does not mean that the infant does not have spastic cerebral palsy. In addition, infants may have more than one motor disorder because spasticity and dystonia often coexist. As the infant’s voluntary activity levels increase, some symptoms may resolve (eg, nonuse of a limb), while other symptoms may worsen (eg, increased involuntary dystonic movements).
posturing in response to voluntary movement). Wherever possible, differentiate between unilateral vs bilateral cerebral palsy early because treatments differ.5,38

False Positives and False Negatives

Without a laboratory biomarker, an early diagnosis is not always clinically clear-cut because of the possibility of false positives and false
negatives. Experienced clinicians acknowledge that, because all infants have an expanding and changing voluntary motor repertoire, determining whether their current motor dysfunction is permanent and causing long-term activity limitations, as per the international definition, is difficult. False negatives can occur for the following reasons: (1) there is a latency between the initial brain lesion and the later onset of clinical neurological signs (eg, exaggerated spasticity or dystonia from voluntary movement), (2) approximately 10% have normal neuroimaging, and (3) half have a seemingly uneventful pregnancy and birth, and (4) one-third have normal neuroimaging, (3) half have a mildest form (GMFCS I) and may initially achieve all of their motor milestones on time, offering false reassurance about their motor development. False positives can also occur because prematurity, stroke, and encephalopathy do not always result in long-term motor disabilities. Australian cerebral palsy population register data indicate that less than 5% of registrations are false-positive diagnoses. In almost all of these instances, the infant was rediagnosed as having another neurological disability (eg, intellectual disability or autism), not a normal developmental outcome.

Eighty-six percent of parents of a child with cerebral palsy suspect it before the clinical diagnosis is made. Population data indicate that seeking to avoid false-positive results by delaying diagnosis is harmful to parent and caregiver well-being. Parents and caregivers dissatisfied with a prolonged diagnostic process are more likely to experience depression and lasting anger. Parents and caregivers acknowledge that, while receiving the diagnosis is always difficult, they prefer to know earlier rather than later so that they can assist in their infant’s development. Early detection is important for the whole family unit because it helps foster acceptance and leads to increased confidence in the infant’s medical team. Early detection allows improved access to early intervention and efficient use of resources.

### Advances in Treatment: Cerebral Palsy-Specific Early Intervention Improves Outcomes

Neuroscience evidence indicates that brain development and refinement of the motor system continue postnatally, driven by motor cortex activity. Early active movement and intervention are essential because infants who do not actively use their motor cortex risk losing cortical connections and dedicated function. Furthermore, there is increasing evidence that the infant’s motor behavior, via discovery and interaction with the environment, controls and generates the growth and development of muscle, ligament, and bone, as well as driving ongoing development of the neuromotor system.

---

Table 2. Clinical Signs Indicating Motor Type and Topography in Infants

<table>
<thead>
<tr>
<th>GMs</th>
<th>Bilateral Spastic Diplegia</th>
<th>Bilateral Spastic Quadriplegia</th>
<th>Dyskinesia</th>
<th>Ataxia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poor repertoire or cramped synchronized GMs, followed by absent fidgety movements</td>
<td>Cramped synchronized GMs, followed by absent fidgety movements</td>
<td>Early onset and long duration of cramped synchronized GMs, followed by absent fidgety movements</td>
<td>Poor repertoire GMs, followed by absent fidgety movements with circular arm movements and finger spreading</td>
<td>Unknown</td>
</tr>
<tr>
<td>MRI</td>
<td>Brain injury (24%)</td>
<td>Malformations (13%)</td>
<td>Unilateral hemorrhage (grade IV)</td>
<td>Lesions in the parietal white matter involving the trigone</td>
</tr>
<tr>
<td></td>
<td>Moderate to severe white matter injury (31%-60%)</td>
<td>Cystic PVL (grade II–III) with sparse or absent myelination of the PLIC</td>
<td>Moderate to severe white matter injury (also known as PVE)</td>
<td>Bilateral white matter injury</td>
</tr>
<tr>
<td></td>
<td>Gray matter injury (34%)</td>
<td>Malformations (16%)</td>
<td>Cystic PVL (grade III) with absent myelination of the PLIC</td>
<td>Gray matter injury</td>
</tr>
<tr>
<td></td>
<td>Moderate to severe white matter injury</td>
<td>Severe white matter injury with or without deep nuclear gray matter</td>
<td>(21%) with thalamic and lentiform nuclear injury</td>
<td>Normal imaging (18%)</td>
</tr>
<tr>
<td></td>
<td>Malformations (16%)</td>
<td>Cerebellar injury</td>
<td>Cerebellar injury</td>
<td></td>
</tr>
</tbody>
</table>

HINE Scores: 50-73 | <50 | <50 | <50 | Unknown |

Motor Tests

- Asymmetrical hand preference
- Stuck in floor sitting (ie, unable to transition out of sitting)
- Cruises or steps consistently in one direction or with the same leg always leading
- Reduced variation in motor behavior
- Good hand function compared with lower limb function
- Dislike or avoidance of floor sitting
- Weight bears on toes
- Reduced variation in motor behavior
- Head lag
- Persistent rounded back in supported sitting
- Bilateral fisted hands
- Slow to reach and grasp with either hand
- Reduced variation in motor behavior
- Twisting arm or neck postures on voluntary movement (may be painful)
- Finds midline play difficult, prefers toys positioned at shoulder width
- Switches hands during reaching task
- Requires a lot of extra time to initiate movement
- Voluntary movement and emotion worsens postures
- Reduced variation in motor behavior
- Non-specific

Abbreviations: CP, cerebral palsy; GMFCS, Gross Motor Function Classification System; GMs, Prechtl Qualitative Assessment of General Movements; HINE, Hammersmith Infant Neurological Examination; MRI, magnetic resonance imaging; PLIC, posterior limb internal capsule; PVE, periventricular echogenicity; PVL, periventricular leukomalacia.
Therefore, the clinical diagnosis of cerebral palsy or high risk of cerebral palsy should always be followed by a referral for the infant to receive cerebral palsy–specific intervention and for the parents or caregivers to receive emotional support. Family concern is a valid reason to trigger formal diagnostic investigations and intervention referrals.

Cerebral palsy–specific early intervention maximizes neuroplasticity and minimizes deleterious modifications to muscle and bone growth and development. Before commencing intervention, unilateral vs bilateral cerebral palsy should be identified because treatments and long-term musculoskeletal outcomes differ. Randomized clinical trial data are beginning to indicate the following: (1) that infants with hemiplegic cerebral palsy who receive early constraint-induced movement therapy (CIMT) have better hand function than controls in the short term and probably substantially better hand function in the long term; (2) that infants with bilateral cerebral palsy who receive regular surveillance and intervention have lower rates of hip displacement, contracture, and scoliosis based on population register data; (3) that infants with any type and topography of cerebral palsy who receive Goals–Activity–Motor Enrichment (GAME), which is an early, intense, enriched, task-specific, training-based paradigm of care for cerebral palsy because they induce neuroplasticity and produce functional gains. Larger replication randomized clinical trials are under way, including the following: (1) Randomised Trial of Rehabilitation Very Early in Congenital Hemiplegia (REACH) (ACTRN12615000180516) (n = 150) CIMT vs bimanual analgesia for procedural pain. Recommendations include pharmacological therapy and environmental interventions for ongoing pain and preemptive analgesia for procedural pain.

Interventions to Prevent Secondary Impairments and Minimize Complications

Regarding pain, procedural pain should be avoided where possible because untreated pain elevates the risk for long-term neuropathic pain. Recommendations include pharmacological therapy and environmental interventions for ongoing pain and preemptive analgesia for procedural pain.

Orthopedics

For hips, anteroposterior pelvic radiographs every 6 to 12 months are recommended commencing at age 12 months. This recommendation is in accord with hip surveillance guidelines.

Neurologic

For epilepsy, standard antiepileptic pharmacological management is recommended.

Urinary Tract

For the bladder, medical investigations should be conducted because abnormal anatomical findings are common. Standard toilet training should be provided over a longer duration because control may take longer.

Sleep

For sleep, specialist assessments and early treatment are recommended before secondary academic and behavioral problems emerge. Examples include sleep hygiene, parental education, spasticity management, melatonin (2.5-10 mg), and gabapentin (5 mg/kg).

Oral Care

For sialorrhea, botulinum toxin A, benztrapine mesylate, or glycopyrrolate should be considered.

Ophthalmologic Issues

Vision can be assessed in the first 48 hours of life using the early assessment of visual function in full-term newborns by Ricci et al. Any infant with abnormal vision at term-equivalent age should receive vision intervention and be reassessed at 3 months. Vision intervention is recommended.

Feeding

For nonoral feeding, swallowing safety should be comprehensively assessed if concerns or clinical history of pneumonia exists because it is the leading cause of death in individuals with cerebral palsy and is mitigated by tube feeding. Weight should be measured regularly because severe physical disability elevates the risk for malnutrition.
Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy

Interventions to Promote Parent or Caregiver Coping and Mental Health

Parental education in behavior management is recommended. An example is the Positive Parenting Program (Triple P). Parent-child attachment interventions are also helpful. Kangaroo Mother Care and music therapy are examples. Finally, parent or caregiver mental health interventions are suggested. One such intervention is Acceptance and Commitment Therapy (ACT).67

Discussion

Clinical Bottom Line

Infants with cerebral palsy require an early diagnosis because motor and cognitive gains are greater from diagnostic-specific early intervention.

An interim diagnosis of high risk of cerebral palsy should be used if a diagnosis of cerebral palsy cannot yet be used with certainty. Clinical signs emerge and evolve before age 2 years. Therefore, a combination of standardized tools should be used to predict risk. Before 5 months’ corrected age, MRI, GMs, or the HINE are most predictive of risk for cerebral palsy.

After 5 months’ corrected age, MRI and the HINE are most predictive of risk for cerebral palsy.

In countries of low to middle income where MRI is not available, the HINE is recommended.

Topography and severity of cerebral palsy are important to establish for clinical purposes. Magnetic resonance imaging and the HINE provide guidance.

False positives occur less than 5% of the time with standardized tools.

False negatives resulting in late diagnoses and late intervention are detrimental to parents, caregivers, and infants.

Limitations

This review article has some limitations. First, our literature search revealed that almost all studies focus on identifying cerebral palsy in infants with newborn discernible risks (eg, prematurity and encephalopathy) because these infants are more often in newborn follow-up. Little has been published about early diagnosis in the 50% of all cerebral palsy cases that are discernible later in infancy after a seemingly uneventful pregnancy and birth because these samples are difficult to assemble. Advances in genetics and understanding of congenital anomalies may provide more clues about how to identify these children earlier. Second, no study to date has investigated the combined predictive power of 3 or more of the individual tools identified in this review article and represents a gap in the literature. Third, we have not reviewed or discussed the literature about evidence-based testing for other childhood disabilities on the differential diagnosis list. Fourth, we have not provided a systematic description of the early intervention evidence. More information on assessment tools and early intervention is contained in a related but separate clinical guideline that is being developed from systematic review data.

Conclusions

Cerebral palsy or high risk of cerebral palsy can be diagnosed accurately and early using clinical reasoning and a combination of standardized tools. High-quality evidence indicates that, for infants with newborn-detectable risks before 5 months’ corrected age, the GMs assessment plus neonatal MRI is more than 95% accurate and is thus recommended. For infants with infant detectable risks after 5 months’ corrected age, the HINE plus neonatal MRI is more than 90% accurate and is therefore recommended. The accuracy of these diagnostic methods in infants with later infancy discernible risks for cerebral palsy is not yet known, but they are conditionally recommended. Accurate early diagnosis is possible even when assessments of GMs are not available or MRI is not safe or affordable (eg, in countries of low to middle income) by using the HINE, which detects cerebral palsy with more than 90% accuracy and provides objective information about severity. Early detection of high risk of cerebral palsy, followed by cerebral palsy-specific early intervention, is recommended and should be the standard of care to optimize infant neuroplasticity, prevent complications, and enhance parent and caregiver well-being.
Author Contributions: Drs Novak and Morgan had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Novak, Morgan, Adde, Blackman, Boyd, Brunstrom-Hernandez, Cioni, Darrah, Eliasson, Ferriero, Forsberg, Gordon, Greaves, Guzzetta, Krumindle-Sundholm, Loughran-Fowlds, Maire, Noritz, Romeo, Shepheard, Spittle, Valentine, Walker, Badawi. Acquisition, analysis, or interpretation of data: Novak, Morgan, Adde, Blackman, Boyd, Cioni, Damiano, de Vries, Einspieler, Fahey, Fehlings, Feters, Fiori, Forsberg, Hadders-Algra, Habourne, Kakooza-Mweiske, Karlsson, Loughran, McIntyre, Pennington, Romeo, Spittle, Thornton, Valentine, White. Drafting of the manuscript: Novak, Morgan, Darrah, Fahey, Guzzetta, Maire, Noritz, Shepheard, Spittle, Walker, Badawi. Critical revision of the manuscript for important intellectual content: Novak, Morgan, Adde, Blackman, Boyd, Brunstrom-Hernandez, Cioni, Damiano, Darrah, Eliasson, de Vries, Einspieler, Fahey, Fehlings, Ferriero, Feters, Fiori, Forsberg, Gordon, Greaves, Guzzetta, Hadders-Algra, Habourne, Kakooza-Mweiske, Karlsson, Krumindle-Sundholm, Loughran, Loughran-Fowlds, Maire, McIntyre, Noritz, Pennington, Romeo, Spittle, Thornton, Valentine, Walker, White, Badawi. Statistical analysis: Novak. Obtained funding: Novak. Administrative, technical, or material support: Novak, Morgan, Adde, Boyd, Einspieler, Feters, Ferriero, Habourne, McIntyre, Shepheard, Spittle, Thornton, Valentine, Walker, White, Badawi. Study supervision: Novak, Adde, Cioni, Eliasson, Ferriero, Fiori, Gordon, Guzzetta, Hadders-Algra, Karlsson, Loughran, Maire, McIntyre, Noritz, Pennington, Romeo, Spittle, Thornton, Valentine, Walker, White, Badawi. Conflict of Interest Disclosures: None reported. Funding/Support: The Cerebral Palsy Alliance Research Foundation funded the face-to-face meeting that enabled the authors to jointly make recommendations from evidence. Dr Guzzetta was supported by grant R 15-96 from the Mariani Foundation of Milan. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Additional Contributions: Koa Whittingham, PhD, and Elena Chorna, MM, MT-BC, CCRP, assisted in retrieving the early intervention evidence. No compensation was received.

REFERENCES


